Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8TAI7
UPID:
REBL1_HUMAN
Alternative names:
Ras homolog enriched in brain like-1 c; Ras homolog enriched in brain-like protein 1; Rheb2
Alternative UPACC:
Q8TAI7; Q56VH8
Background:
GTPase RhebL1, also known as Ras homolog enriched in brain like-1 c, plays a pivotal role in cellular processes by binding GTP and exhibiting intrinsic GTPase activity. It is instrumental in activating NF-kappa-B-mediated gene transcription and promotes signal transduction through MTOR, further activating RPS6KB1. RhebL1 functions as a downstream target of the small GTPase-activating proteins TSC1 and TSC2.
Therapeutic significance:
Understanding the role of GTPase RhebL1 could open doors to potential therapeutic strategies.